We describe a research technique for fiberoptic bronchoscopy with bronchoalveolar lavage (BAL) using manual hand held suction in order to remove nonadherent cells and lung lining fluid from the mucosal surface. In research environments, BAL allows sampling of innate (lung macrophage), cellular (B-and T-cells), and humoral (immunoglobulin) responses within the lung.
Introduction

Background
Fiberoptic bronchoscopy was developed for clinical practice; it is widely used both diagnostically and therapeutically 1, 2 . Bronchoalveolar lavage (BAL) removes nonadherent cells and lung lining fluid from the mucosal surface; biopsy is used to sample mucosal and submucosal tissues. In research environments, BAL allows sampling of innate (lung macrophages [3] [4] [5] ), cellular (B-and T-cells 6 ), and humoral (immunoglobulin 7 ) responses within the lung.
BAL is internationally accepted for research purposes 8 and since 1999 the technique has been performed in >1,000 subjects in the UK and Malawi by our group. We use this technique in studies of innate, cellular, and humoral immune responses to pneumococcal antigen including experimental human pneumococcal carriage 9, 17 , biomass smoke 5 , HIV and vaccination, and adjunct treatment studies into recovery from pneumonia. Our technique uses gentle hand-held suction of instilled fluid; this is designed to maximize BAL volume returned and apply minimum shear force on ciliated epithelia in order to preserve the structure and function of cells within the BAL fluid. and preserve viability to facilitate the growth of cells in ex vivo culture. For these reasons the research technique uses a larger volume instillate (typically in the order of 200 ml) and employs manual suction to reduce cell damage. Patients are given local anesthetic, offered conscious sedation (midazolam), and tolerate the procedure well with minimal side effects. Verbal and written subject information improves tolerance and written informed consent is mandatory 1 .
Goal
The overall goal is that the procedure should be safe and effective. Subjects should not experience any physiological disturbance and operators should consistently collect in excess of 100 ml of BAL from subjects. After the procedure, subjects should experience minimal side effects.
Safety
Safety of the subject is paramount. Subjects are carefully selected using clear inclusion and exclusion criteria. This protocol includes a description of the potential risks and the steps taken to mitigate them.
Contraindications to research bronchoscopy may be expressed as absolute or relative, and are included in our study protocol as exclusion and inclusion criteria. Our subjects are all screened to ensure full health.
Absolute contraindications include unstable cervical spine, unresponsive hypoxia, unstable angina, bleeding diathesis, and malignant cardiac arrhythmia.
Relative contraindications, including those conditions associated with increased complication rates, include:
General: poorly cooperative subject Other: immunosuppression (our group regularly performs this procedure in HIV positive subjects).
See Table 1 -Risks associated with BAL for research.
Protocol
The Subjects are Met on Arrival by the Respiratory Research Nurse
1. The subject has been fasting for >4 hr for solid food and 2 hr for clear fluids 1 . 2. The procedure is performed as a day case with appropriate pre-and post-procedure checks (as per standard hospital policy). 3. The subject wears a hospital gown. 4. A small gauge cannula is inserted (ideally into the left hand) and remains in situ until the end of the post-procedure recovery period 1 . 5. Preprocedure observations are taken (blood pressure, heart rate, oxygen saturations [sats]). 6. The subject is transferred to the bronchoscopy suite.
The Subject is Prepared for the Procedure in the Suite by a Respiratory Research Clinician Experienced in Bronchoscopy
1. Monitoring equipment is attached including; 3-lead ECG, pulse oximeter 1,10 and sphygmomanometer. Anesthetic support is not needed including written informed consent. 2. Oxygen may be delivered via nasal cannula at up to 4 L/min, to achieve sats >90% 1 . 3. The operator checks the bronchoscope, this includes ensuring effective suction by aspirating sterile normal saline. 4. Topical anesthesia with lidocaine is achieved in the nasal passages (using Instillagel 1 ) and the oral mucosa (using xylocaine) 5. If sedation is appropriate and requested by the subject, intravenous midazolam is administered 1 . An appropriate reversal agent (flumazenil) is immediately available. 6. Resuscitation equipment should be readily available 1, 10 .
The Bronchoscope is Inserted and Positioned
Subject Recovery
1. The subject is recovered for 2-4 hr by the respiratory research nurse on a ward. 2. During this time they are allowed to rest and then only eat and drink >60 min 1 after the procedure (when their swallow is assessed as safe), in order reduce the risk of aspiration. 3. Post procedural observations are monitored and recorded. A clinical examination occurs prior to discharge. 4. The subject is briefed predischarge about the common side effects (fever, mild right submammary chest discomfort, sore throat) and given a contact number in case significant side effects occur 1 . 5. The subject is followed-up at 1-5 days post-procedure with a clinical contact. This may be either over the telephone or in person. 6 cells/ml), introduced by pipetting into appropriate tissue culture plates, and incubated at 37 °C for 3 hr to allow macrophage adherence. 1 ml of this cell suspension per well is appropriate for 24-well culture plates. 5. For lymphocyte work, after 3 hr of incubation, the culture medium is gently pipetted up and down 3x, and collected. This medium contains lymphocytes and nonadherent macrophages and may be used to assess lymphocyte function; it may also be used in purification steps e.g. with CD14 magnetic beads to remove macrophages. 6. For macrophage work, after 3 hr of incubation, the medium is carefully removed with minimal pipetting and replaced with fresh, warm medium without antibiotics (RPMI 1640 + 10% fetal bovine serum + 2 mM L-glutamine). The macrophages are adherent to the tissue culture plate (see Figure 1) . * Not experienced in our group in over 1,500 research procedures. † Idiosyncratic rather than dose-dependent reaction.
# Our group's experience in over 1,500 research procedures. Table 1 . Risks associated with BAL for research. This includes the hazard or risk and how this is reduced by using the described technique. Effects of the bronchoscopy/BAL and also the effects of any medicinal drugs used are included. 
Discussion
In order to achieve good results the following are helpful:
1. Good anesthetisation at the base of the tongue and posterior oropharynx. This is important because it improves the subject's procedural tolerance and overall comfort. 2. Either a pediatric (outer diameter 3.4-3.6 mm) or adult bronchoscope (outer diameter 4.8-5.9 mm) can be used. 3. If there is any discomfort during nasal intubation, oral intubation is preferred. In general nasal intubation is either a straightforward technique or should be abandoned. 4. After initial instillation of lidocaine to the oropharynx, the subject may prefer the bronchoscope to be withdrawn pending the onset of anesthesia, especially if the bronchoscope is inserted orally. 5. Ensure at least 10 x 10 ml syringes are prefilled with only 2-4 ml of lidocaine. Air should be left in the syringes allowing improved delivery of the anesthesia directly onto cords and endobronchial mucosa. 6. Since coughing during the procedure significantly reduces BAL yield; using warmed saline and having good mucosal anesthesia are important to reduce this. 7. The 50 ml syringes must be prefilled with warmed saline. It is common for the first 50 ml of normal saline instilled to yield between 10-20 ml due to dead-space loss and the remainder running into the terminal airways. Further aliquots return a greater proportion of fluid. 8. The operator should always check the bronchoscope prior to intubation, including ensuring effective suction by aspirating sterile normal saline. Loss of suction can commonly occur due to kinking of the tube or leaks around the connections with the bronchoscope or suction device. 9. During manual suction, ideally the airway should not collapse. If suction recurrently collapses the airway, BAL returns are reduced to a valve mechanism, and local inflammation and bleeding is more likely: this in turn makes the airways more irritable and cough more likely. Choosing the most appropriate RML subsegmental branch and using low suction pressures are therefore both important. 10. When air is constantly aspirated recheck the connection of the syringe to the bronchoscope and also the position of the bronchoscope in the distal airway. If this is a recurrent problem, post-procedure ensure that there are no holes in the bronchoscope itself. 11. BAL from smokers is often darker due to the presence of intracellular particulates. Smokers may tolerate the bronchoscopy less well, and have increased cough. 12. The preferable BAL volume yield is >100 ml. A yield of >150 ml is excellent. We have not experienced any yields >170 ml. There is no linear relationship between the cell yield and BAL volume yield. 13. Yields of <100 ml are, in our experience, more likely to lead to side effects such as cough, chest pain and fever. We advise that subjects with yields of <100 ml be recovered in the left lateral position, this may aid drainage of any remaining lung fluid. 14. Clinical contact should be made with the subject within 1-5 days to ensure no side effects. 15. Midazolam sedation is used for <50% of subjects in the UK and <5% in Malawi. Midazolam does not appear to directly improve the tolerability; some operators feel that sedation may sometimes be counterproductive in maintaining a coherent (and reassuring) dialogue with the subject. 16. In our experience, there is a significant learning curve with this technique. For example coordination between doctor and nurse takes time and yields are often lower at the beginning of the learning process.
